Cognitive pharmacotherapy of Alzheimer's disease and other dementias

Canadian Journal of Psychiatry

Volumn 47, Issue 8, 2002, Pages 715-722

  Herrmann, Nathan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Cognitive enhancer; Dementia; Therapy

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; FOLIC ACID; GALANTAMINE; RIVASTIGMINE; VITAMIN B COMPLEX;

ALZHEIMER DISEASE; CAREGIVER; COGNITIVE DEFECT; COGNITIVE THERAPY; DEMENTIA; DIABETES MELLITUS; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MEDLINE; MULTIINFARCT DEMENTIA; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; STROKE;

EID: 0036808836     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370204700802     Document Type: Review

References (91)

1. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: Study methods and prevalence of dementia. CMAJ 1994;150:899-913.
2. Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology 2000;55:66-73.
3. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between disease severity and costs of caring. CMAJ 1998;159:457-65.
4. Ostbye T, Crosse E. Net economic costs of dementia in Canada. CMAJ 1994;151:1457-64.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM IV). 4th Ed. Washington (DC): The American Psychiatric Association; 1994.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
7. Yaffe K, Bames D, Nevitt M, Lui LY, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: Women who walk. Arch Intern Med 2001;161:1703-8.
8. Wilson RS, Mendes deLeon CF, Barnes LL, Schneider SA, Bienias JL, Evans DA, and others. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002;287:742-8.
9. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001;28(Suppl 1):S96-S107.
10. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention. Neurology 1998;51(Suppl 1):S53-S60.
11. Felician O, Sandson TA. The neurobiology and pharmacotherapy of Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1999;11:19-31.
12. Koopmans Summers W, Majoviski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. NEJM 1986;315:1241-5.
13. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996;7:293-303.
14. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
15. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebocontrolled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31.
16. Bums A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, and others. The effects of donepezil in Alzheimer's disease results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
17. Winblad B, Engedal K, Soininen H, Verhey F, Waldermar G, Wimo A, and others. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
18. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama J, and others. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000;11:299-313.
19. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, and others. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8.
20. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20.
21. Agid Y, Dubois B. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res 1998;59:837-45.
22. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, and others. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318(7184):633-8.
23. Corey-Bloom J, Anand R, Veach J. ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Ger Psychopharmacol 1998;1:55-65.
24. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54(12):2261-8.
25. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321(7274):1445-9.
26. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and others. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
27. Wilkinson D, Murray J. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:852-7.
28. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Nurosurg Psychiatry 2001;71:589-95.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
30. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
31. Stem RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, and others. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-6.
32. Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: A meta-analysis. Int Psychogeriatr 2000;12:231-47.
33. Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapy. Alzheimer Dis Assoc Disord 1999;13(Suppl 2):S9-S19.
34. O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, and others. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999;47:570-8.
35. Getsios D, Caro JJ, Caro G, Ishak, K. Assessment of health economics in Alzheimer's disease (AHEAD): Galantamine treatment in Canada. Neurology 2001;57:972-8.
36. Giacobini E. Do cholinesterase inhibitors have disease modifying effects in Alzheimer's disease? CNS Drugs 2001;15:80-91.
37. Borroni B, Colciagli F, Pastorino L, Pettenati C, Cottini E, Rozzini L, and others. Amyloid precursor protein in platelets of patients with Alzheimer disease. Arch Neurol 2001;58:442-6.
38. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCL and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(Suppl 1):25-9.
39. Tiseo PJ, Perdoma CA, Friedhoff LT. Concurrent administration of donepezil HCL and lectoconazole: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(Suppl 1):30-4.
40. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCL and theophylline: Assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998;46(Suppl 1):35-9.
41. Tiseo PJ, Perdoma CA, Friedhoff LT. Concurrent administration of donepezil HC Land digoxin: Assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998;46(Suppl 1):40-4.
42. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCL on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46(Suppl 1):45-50.
43. Grossberg GT, Shahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-7.
44. Compendium of Pharmaceuticals and Specialties 2002: The Canadian Drug Reference for Health Professionals. Product Monograph.
45. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002;17:288-9.
46. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, and others. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999;281:1401-6.
47. McKeith IG, Del Ser T, Spano P, Emre M, Wesnes L, Anand R, and others. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised double blind placebo controlled international study. Lancet 2000;356:2031-6.
48. Lanctôt KL, Herrmann N. Donepezil for behavioral disorders associated with Lewy Bodies: A case series. Int J Geriatr Psychiatry 2000;15:338-45.
49. Maclean LE, Collins CC, Byme EJ. Dementia with Lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms and sleep. Int Psychogeriatr 2001;13:277-88.
50. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CRV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359.
51. Litvan I. Therapy and management of frontal lobe dementia patients. Neurology 2001;56(Suppl 4):S41-S45.
52. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467-73.
53. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997;48(Suppl 7):527-35.
54. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology 1977;48(Suppl 2):S21-S26.
55. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997;48(Suppl 7):S36-S41.
56. Taber KH, Murphy DD, Blurton-Jones MM, Hurley RA. An update on estrogen: Higher cognitive function, receptor mapping, neurotrophic effects. J Neuropsychiatry Clin Neurosci 2001;13:313-7.
57. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, and others. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
58. Mulnard, RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, and others. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. JAMA 2000;283:1007-15.
59. Marder K, Sano M. Estrogen to treat Alzheimer's disease: Too little, too late? Neurology 2000;54:2035-7.
60. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, and others. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207-13.
61. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, and others. High-dose estradiol improves cognition for women with AD: Results of a randomized study. Neurology 2001;57:605-12.
62. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
63. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, and others. Testoterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001;57:80-8.
64. Aisen PS. Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontology 1997;43:143-9.
65. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-32.
66. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, and others. Clinical trial of indomethicin in Alzheimer's disease. Neurology 1993;43:1609-11.
67. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
68. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, and others. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-93.
69. Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ, Scheltens PK. Effects of hydroxchloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455-60.
70. Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, and others. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
71. Marksbery WR. The role of oxadative stress in Alzheimer's disease. Arch Neurol 1999;56:1449-52.
72. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Gundman M, and others. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. NEJM 1997;336:1216-22.
73. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
74. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001;57:1515-7.
75. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Marksbery WR. Brain infarction and the clinical expression of Alzheimer disease: The nun study. JAMA 1997;277:813-7.
76. Guo Z, Fratiglioni L, Zhu L, Fastlom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol 1999;56:991-6.
77. Forette F, Seux ML, Staessen JA, Thys L, Birkenhager WH, Babarskiene MR, and others. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998;35:1347-51.
78. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
79. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, and others. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. NEJM 2002;346:476-83.
80. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997;278:1327-32.
81. Canadian Coordinating Office for Health Technology Assessment. Drug Treatments for Alzheimer's Disease: Efficacy Outcome Measurements and Cost-Effectiveness; 2001.
82. Bae CY, Cho CY, Cho K, Oh BH, Choi KG, Lee HS, and others. A double-blind, placebo-controlled multicenter study of cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000;48:1566-71.
83. Reuther E, Husmann R, Kinzler E, Diabl E, Kingler D, Spatt J, and others. A 28 week, double-blind, placebo-controlled study with cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 2001;16:253-63.
84. Winblad B, Poritis W. Memantine in severe dementia: Results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46.
85. Schenk DB, Seubert P, Lieberburg I, Wallace J. β-Peptide immunization: A possible new treatment for Alzheimer disease. Arch Neurol 2002;57:934-6.
86. Woolf SH, Grol R, Hutchinson A, Eccles M, Grunshaw J. Potential benefits, limitations, and harms of clinical guidelines BMJ 1999;318:527-30.
87. American Psychiatric Association. Practice guideline for the treatments of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154(Suppl):1-39.
88. Small GW, Rabins PV, Barry PP, Buckholt: NS, Dekosky ST, Ferris SH, and others. Diagnosis and treatment of Alzheimer disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
89. Patterson CJS, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman H, and others. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian consensus conference on dementia. CMAJ 1999;160 (Suppl 12):S1-S15.
90. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-16.
91. Herrmann N. Pharmacotherapy for Alzheimer's disease and other dementias. Curr Opin Psychiatry 2002;15:403-9.